Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» This Cancer Drug Candidate Could Be a Hit for Pfizer
This Cancer Drug Candidate Could Be a Hit for Pfizer
This Cancer Drug Candidate Could Be a Hit for Pfizer
Submitted by
admin
on March 26, 2023 - 11:19pm
Source:
Motley Fool
News Tags:
Pfizer
elranatamab
Multiple Myeloma
Headline:
This Cancer Drug Candidate Could Be a Hit for Pfizer
snippet:
Elranatamab showed itself to be an effective therapy for multiple myeloma patients.
The drug candidate has great potential in a market estimated at some $20 billion.
Pfizer’s 4%-plus dividend yield could also be enticing to income investors.
Do Not Allow Advertisers to Use My Personal information